Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Hold” by Analysts

Shares of Blueprint Medicines Co. (NASDAQ:BPMC) have been assigned an average recommendation of “Hold” from the fifteen analysts that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $94.87.

A number of research analysts have recently issued reports on BPMC shares. HC Wainwright boosted their price objective on Blueprint Medicines from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday. JMP Securities boosted their price target on Blueprint Medicines from $114.00 to $125.00 and gave the company a “market outperform” rating in a research note on Friday. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday. Stifel Nicolaus boosted their target price on shares of Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Finally, Barclays increased their target price on shares of Blueprint Medicines from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday.

Blueprint Medicines Stock Up 0.2 %

Shares of BPMC opened at $107.19 on Tuesday. The business has a 50-day moving average of $91.77 and a 200-day moving average of $80.52. The company has a debt-to-equity ratio of 1.60, a quick ratio of 3.66 and a current ratio of 3.76. Blueprint Medicines has a 1 year low of $43.89 and a 1 year high of $110.93.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. The company had revenue of $71.96 million for the quarter, compared to analyst estimates of $67.34 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 215.07%. The company’s quarterly revenue was up 85.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.65) EPS. Equities research analysts anticipate that Blueprint Medicines will post -5.41 EPS for the current fiscal year.

Insider Transactions at Blueprint Medicines

In other news, insider Christopher K. Murray sold 621 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $93.65, for a total value of $58,156.65. Following the transaction, the insider now owns 36,374 shares in the company, valued at $3,406,425.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Christopher K. Murray sold 621 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $93.65, for a total value of $58,156.65. Following the completion of the sale, the insider now owns 36,374 shares in the company, valued at $3,406,425.10. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Christopher K. Murray sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $100.00, for a total transaction of $500,000.00. Following the transaction, the insider now owns 24,495 shares in the company, valued at $2,449,500. The disclosure for this sale can be found here. Insiders sold a total of 92,289 shares of company stock valued at $8,314,163 over the last ninety days. 3.88% of the stock is currently owned by insiders.

Institutional Trading of Blueprint Medicines

Institutional investors and hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. grew its stake in Blueprint Medicines by 63.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 329 shares during the period. Cutler Group LLC CA grew its position in Blueprint Medicines by 1,685.7% during the third quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 944 shares during the period. Compass Wealth Management LLC purchased a new stake in Blueprint Medicines during the fourth quarter worth about $69,000. China Universal Asset Management Co. Ltd. raised its position in Blueprint Medicines by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 757 shares during the period. Finally, Van ECK Associates Corp boosted its stake in Blueprint Medicines by 28.4% in the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 193 shares during the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.